After the 95th, he served as CEO CEO of 10 billion listed companies!At the age of 27, he was accused of 29.7 billion yuan

Blue words, reference to Zhengshang reference.

BY Zhengshang Reference (WeChat's best financial reading, passing political and economic information from a professional perspective, in-depth interpretation of financial news, here you can understand more real China) WeChat: ZSNC-OK

The sudden office of the "new head" after the 95s made the outside world look forward to and curious about the future development of Chinese biopharmaceuticals.

Source: Newfortune comprehensive comprehensive self -comprehensive self -comprehensive self -consignment China, Finance Network, Siqi Club, etc.

On July 28, the Chinese biopharmaceuticals of the Hong Kong stock listed company appointed the new CEO, and the young post -95 young man Xie Chengrun announced his office. He is the son of Xie Bing, the founder of Chinese biopharmaceutical, and the brother of the company's current board chairman Xie Qirun.

It is understood that after taking over as the CEO of China Biopharmaceuticals, Xie Chengrun will carry out four strategic development of the four strategic development of the four strategic development of "organizational integration of Integration, comprehensive innovation Innovation, international Globalization, digital Digitalization".

The division of work of Sister Xie's brother and brother is that the chairman of the board of directors Xie Qirun will focus on the group's strategic planning, international business, capital market operation, and related affairs of listed companies. Organization optimization and improvement.

01

After the 95th "new head" on the stage, the first show

On the evening of July 27, China Biopharmaceutical, a listed company of Hong Kong stocks, stated that Xie Chengrun was appointed as the company's chief executive and officially performed his duties on July 28. Li Yi, an executive director and CEO of Chinese Biopharmaceuticals, no longer held the above position because he intends to focus on the development of other causes, but he is also hired as a senior consultant of the company.

According to the information disclosed by Chinese biopharmaceuticals, Li Yi worked in JP Morgan Chase for 5 years before performing his duties, and was appointed as China's first foreign -funded joint venture securities company Morgan Chase Securities (Morgan Datong Securities (in September 2019 ( Chairman of China) Co., Ltd..

Two years ago, Li Yi replaced Xie Bing as the chief executive of Chinese biopharmaceuticals.

China Biopharmaceutical Announcement pointed out that in the past two years, Li Yi has brought the company's useful experience to the company's capital operations. Through strategic sorting out, Li Yi has effectively improved the overall efficiency of the Group. In the next stage, as a senior consultant, Mr. Li will use his rich experience in the global financial investment field to help the international development of China's biopharmaceutical business, and give effective suggestions in formulating corporate strategy, investment and financing strategies.

At that time, in Li Yi's performance contract, its preliminary term was set to be three years. According to media reports, Li Yi joined the company's biopharmaceuticals in the first year to receive a total of at least 9 million US dollars, and the contract was RMB 60 million.

Public information shows that Xie Chengrun was born in August 1995 and joined China Biopharmaceutical in June 2018. He is currently a member of the company's CEO, Executive Director, and Executive Directors Committee. As of now, Xie Chengrun holds about 21.53%of Chinese biopharmaceuticals with its wholly -owned company.

The resume shows that Xie Chengrun has a bachelor's degree in economics from the University of Wharton School of Business at the University of Pennsylvania, and a master's degree in management and global leadership degree from the Su Shimin College of Tsinghua University. During the university studies, Xie Chengrun founded the Bin Da Wharton Summit and established the China Summit Foundation at the end of 2016. In 2017, Xie Chengrun, who was only 22 years old, also served as the CEO of North America as a well -known human resources company.

02

New management focuses on the four strategies

It is understood that after taking over the CEO, Xie Chengrun will focus on the four strategies of "organizing integration of Integration, comprehensive innovation Innovation, international Globalization, and digital Digitalization". Integration, etc.; Comprehensively coordinate management groups; build a professional management team to further improve organizational efficiency, drive innovation business, connect external cooperation, and promote global innovation.

It is worth noting that Xie Chengrun's sister Xie Qirun had previously served as the chairman of the board of directors in 2015. Since then, the performance and market value of Chinese biopharmaceuticals have increased significantly. In 2021, China's biopharmaceuticals achieved operating income of 26.861 billion yuan, an increase of 13.6%year -on -year; net profit of home mother was 14.608 billion yuan, an increase of 427.2%year -on -year.

On the evening of March 31, 2022, China Biopharmaceutical Company released the 2021 annual report. Once released, it attracted great attention and enthusiastic discussions.

The report shows that the company's total annual revenue is about 26.8 billion yuan, an increase of about 14 % year -on -year, and its net profit is about 14.6 billion yuan, which is about 4 times compared to 2020.

In this context, how the new management with the two management of Sister Xie's and brother is the focus of the future management of the new management.

"The chairman of the board of directors and CEOs focus on the division of labor, and will lead the consensus of Chinese biopharmaceuticals to innovate and forge ahead, and create value for patients, shareholders, and society." Chinese biopharmaceuticals say Focus on the Group's strategic planning, international business, capital market operations, and related affairs of listed companies. CEO Mr. Xie Chengrun will focus on the operation management, organizational optimization and effectiveness of all subsidiaries of listed companies. China Biopharmaceutical Co., Ltd. is one of the domestic pharmaceutical groups. The business line covers biopharmaceuticals, chemical drugs, and modern Chinese medicine modern preparations, especially in the field of liver disease, tumor, and cardiovascular and cerebrovascular vascular. The subsidiaries include Zhengda Tianqing Pharmaceutical Group, Beijing Tede Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, Jiangsu Zhengdafenghai Pharmaceutical, Qingdao Zhengda Haier Pharmaceutical, Jiangsu Zhengda Qingjiang Pharmaceutical, Beijing Zhengda Oasis Medicine Technology Co., Ltd. Enterprise.

In fact, although Xie Chengrun was very young, as early as 2019, he has begun to be the director of Zhengda Tianqing Pharmaceutical Group Co., Ltd. ("Zheng Datian Qing"), and in July 2020 Essence

It is worth noting that in 2019, Xie Chengrun's father Xie Bing and his mother Zheng Xiangling transferred about one -fifth of the company's company shares with a family business "Chinese Biopharmaceutical", and transferred to Xie Chengrun's name by gift. The value of the net worth was 27.8 billion yuan, becoming the richest man in the post -95s of China. In the 2022 New Fortune 500 rich people, the Xie family ranked 119th with total wealth of 35.29 billion yuan.

03

The legendary "Xie family"

The history of Chinese biopharmaceuticals and the Xie family's family behind it is quite legendary, and there is a well -known Zhengda Group behind it. According to the China Fund, Zhengda Group was created by Xie Yichu, a Thai overseas Chinese in Guangdong, in Guangdong. He had four sons, named Xie Zhengmin, Xie Damin, Xie Zhongmin, Xie Guomin.

Xie Bing, the son of Xie Zhengmin among the four brothers, entered the medical and health industry and was the founder of Chinese biopharmaceuticals. The official website shows that China Biopharmaceutical was listed on the Hong Kong Stock Exchange in 2000. The core companies include a series of companies such as Zhengda Tianqing, Nanjing Zhengda Tianqing, Beijing Ted Pharmaceutical, and Zhengdafenghai.

It is worth noting that Xie Bing's wife Zheng Xiangling is also a legend.

In 1978, 14 -year -old Zheng Xiangling was attracted by the Shaanxi Military Region for her special function and was specially recruited to join the army. Since then, she has embarked on the road of medical research. In 1988, Zheng Xiangling officially retired after completing all his studies, and met her husband Xie Bing in a coincidence. In 1995, Beijing Tede Pharmaceutical Co., Ltd. was established, and Zheng Xiangling was the chairman of the company. During this period, she went to the world to inspect all over the world, and also invited some colleagues with scientific research specialties in the troops to participate. After two years of unremitting efforts and leading scientific research teams, Beijing Tede has become a high -tech pharmaceutical company with independent research and development, production, testing, and listing.

Since 2015, Chinese biopharmaceuticals have begun to enter new and old alternation. At that time, Xie Bing's daughter and 23 -year -old Xie Qirun became chairman and executive director of the board of directors of Chinese biopharmaceuticals.

As Xie Chengrun became the commander of the CEO of Chinese Biopharmaceuticals, Chinese biopharmaceuticals have been operated by the "fourth generation" in front of the stage.

- END -